13 of 112 unique stocks in common · Jaccard: 11.6%
A weighted portfolio overlap of 23.89% indicates a moderate overlap (a meaningful shared core). This means that out of every ₹100 you invest across these two schemes, approximately ₹23.89 is allocated to the exact same companies at the same relative proportions. The schemes share 13 common holdings.
The largest overlapping asset in their portfolios is Reliance Industries, which commands a weight of 8.46% in Tata Nifty500 Multicap India Manufacturing 50-30-20 Index Fund and 8.25% in UTI Nifty 50 ETF. Holding both schemes increases your concentration in Reliance Industries rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Tata | in UTI |
|---|---|---|
| Reliance IndustriesPetroleum Products | 8.46% | 8.25% |
| Mahindra & MahindraAutomobiles | 5.77% | 2.52% |
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | 4.04% | 1.76% |
| Maruti Suzuki IndiaAutomobiles | 3.65% | 1.59% |
| Tata SteelFerrous Metals | 3.64% | 1.59% |
| Hindalco IndustriesNon - Ferrous Metals | 3.46% | 1.51% |
| Bharat ElectronicsAerospace & Defense | 3.12% | 1.36% |
| JSW SteelFerrous Metals | 2.54% | 1.11% |
| Bajaj AutoAutomobiles | 2.46% | 1.07% |
| Eicher MotorsAutomobiles | 2.09% | 0.91% |
| Tata Motors Passenger VehiclesAutomobiles | 1.75% | 0.76% |
| CiplaPharmaceuticals & Biotechnology | 1.67% | 0.73% |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | 1.68% | 0.73% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.